Envista (NYSE:NVST) Stock Rating Lowered by Wall Street Zen

Envista (NYSE:NVST) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. increased their target price on Envista from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday. Stifel Nicolaus set a $25.00 price objective on Envista in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Envista in a research note on Monday. Zacks Research lowered Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Finally, Robert W. Baird set a $27.00 target price on Envista in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $21.77.

Envista Trading Up 0.1%

Shares of Envista stock opened at $22.27 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.37 and a quick ratio of 2.02. The stock has a market capitalization of $3.66 billion, a PE ratio of 247.47, a P/E/G ratio of 1.09 and a beta of 1.02. Envista has a 1-year low of $14.22 and a 1-year high of $22.68. The company’s fifty day simple moving average is $20.35 and its 200-day simple moving average is $20.25.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Envista had a net margin of 0.58% and a return on equity of 5.90%. The business had revenue of $669.90 million during the quarter, compared to analyst estimates of $639.49 million. During the same period in the prior year, the business posted $0.12 earnings per share. The company’s revenue was up 11.5% on a year-over-year basis. As a group, equities analysts anticipate that Envista will post 1 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in Envista by 34.3% during the third quarter. GAMMA Investing LLC now owns 2,498 shares of the company’s stock worth $51,000 after purchasing an additional 638 shares in the last quarter. Claret Asset Management Corp grew its holdings in shares of Envista by 6.5% in the second quarter. Claret Asset Management Corp now owns 11,827 shares of the company’s stock valued at $231,000 after purchasing an additional 724 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Envista by 35.3% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,041 shares of the company’s stock valued at $62,000 after acquiring an additional 793 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Envista by 317.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after purchasing an additional 1,026 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in Envista by 5.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 20,100 shares of the company’s stock worth $393,000 after buying an additional 1,067 shares during the period.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.